What is the present valuation and projected CAGR of the female infertility market?
The female infertility market size has grown steadily in recent years. It will grow from $1.79 billion in 2024 to $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to growing trend of women delaying childbirth, increasing changes in lifestyle, increasing government initiatives, rising aging population, increasing assisted reproductive technology (ART) treatment.
The female infertility market size is expected to see steady growth in the next few years. It will grow to $2.19 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising awareness of fertility issues, increasing cases of polycystic ovary syndrome, rising cases of uterine abnormalities, rising incidence of genetic disorders, increasing obesity. Major trends in the forecast period include advancements in preimplantation genetic testing, technological advancement, novel technologies for diagnosis, fertility preservation, and telemedicine.
Get Your Free Sample of The Global Female Infertility Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp
What key drivers have fueled the female infertility market’s development over the years?
The increasing prevalence of infertility is expected to propel the growth of the female infertility market going forward. Infertility is the inability to conceive after 12 months of regular, unprotected sexual intercourse. Increasing infertility is driven by factors such as delayed childbearing, lifestyle changes, environmental toxins, rising obesity, and higher stress levels. Female infertility treatment is required to address and manage underlying medical, hormonal, or structural issues that impair fertility, thereby enhancing the chances of conception and preventing permanent infertility. For instance, in July 2024, according to the Human Fertilization and Embryology Authority, a UK-based non-departmental public body of the Department of Health and Social Care, licensed fertility clinics in the UK performed nearly 77,000 fresh and frozen embryo transfer IVF cycles for 52,500 patients in 2022. Over 90% of these patients underwent treatment with a partner, involving approximately 100,000 individuals. Therefore, the increasing prevalence of infertility drives the growth of the female infertility market.
What is the segmentation for the female infertility market?
The female infertility market covered in this report is segmented –
1) By Treatment: Clomiphene Citrate, Gonadotropins, Metformin, Letrozole, Bromocriptine
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
3) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Clomiphene Citrate: Oral Clomiphene Citrate, Injectable Clomiphene Citrate
2) By Gonadotropins: Recombinant Gonadotropins, Urinary Gonadotropins, Human Chorionic Gonadotropin (hCG)
3) By Metformin: Immediate-Release Metformin, Extended-Release Metformin
4) By Letrozole: Oral Letrozole Tablets, Injectable Letrozole
5) By Bromocriptine: Oral Bromocriptine Tablets, Intranasal Bromocriptine
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report
Who are the most influential companies in the female infertility market?
Major companies operating in the female infertility market are Pfizer Inc., Roche Holding AG, Merck And Co. Inc, Bayer AG, Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Commonwealth Serum Laboratories Ltd, Organon Theramex, Juniper Reproductive Health Ltd., Sumitomo Pharma, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Co., Mankind Pharma, Kissei Pharmaceutical Co Ltd, ASKA Pharmaceutical Co. Ltd., Fuji Pharma Co. Ltd., ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Hernova Lifesciences Holdings Ltd
What are the top industry trends projected to impact the female infertility market?
Major companies operating in the female infertility market are focusing on developing innovative products, such as non-invasive diagnostic tests, to gain a competitive edge in the industry. A non-invasive diagnostic test is a medical test that detects conditions or diseases without requiring surgery or penetration of the body. For instance, in August 2024, Heranova Lifesciences, a US-based biotech company, launched an early access program for HerResolve, a non-invasive diagnostic test for endometriosis. Endometriosis affects about 200 million women worldwide, causing symptoms like infertility, pain, and bleeding. For many women, an accurate diagnosis takes an average of 7-10 years from the onset of symptoms, mainly due to the varied symptom presentation and the invasive nature of the most reliable diagnostic method, exploratory laparoscopic surgery. HerResolve potentially reduces this diagnostic delay from years to months, leading to better patient and healthcare outcomes. HerResolve aims to shorten this timeline significantly, improving patient care and outcomes.
What are the major regional insights for the female infertility market, and which region holds the top position?
Europe was the largest region in the female infertility market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Female Infertility Market Report 2025 Offer?
The female infertility market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Female infertility is defined as the inability of a woman to conceive after 12 months of regular, unprotected sexual intercourse (or 6 months for women aged 35 or older) or the inability to carry a pregnancy to term. It is a complex condition resulting from various factors affecting the reproductive system.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20787
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
